Poland· PL-100193964

Pyrazinamid Farmapol

A pyrazinamide product containing pyrazinamidum, registered in Poland by Przedsiębiorstwo Farmaceutyczne Farmapol Sp. z o.o.. The same ATC class is registered in 14 of our 19 countries.

ATC J04AK01

Checked against URPL (Poland) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about pyrazinamidumAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Pyrazinamide is registered in 14 of 19 countries.

Countries holding a registration under ATC J04AK01 (pyrazinamide), each read from that country’s own register.

This record: Poland, from URPL (Poland)
8 of them publish a price we can compare per daily dose

Search pyrazinamide products by name

Pyrazinamide · ATC J04AK01

14 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of pyrazinamide costs, country by country.

Normalised to the WHO defined daily dose (1.5 g), the median price runs from $0.61 in France to $3.20 in Switzerland — a ×5.2 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Pyrazinamide · price per daily dose (1.5 g)

USD · FX 28 Sept 2026

CH Switzerland$3.20
FR France$0.61

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)

Active substance: Pyrazinamidum
Manufacturer: Przedsiębiorstwo Farmaceutyczne Farmapol Sp. z o.o.
Country: Poland (PL)
ATC code: J04AK01
ATC class: Pyrazinamide
Defined daily dose: 1.5 g, O
Reimbursed: Not published by this register
Source register: URPL (Poland)
Last checked: September 27, 2026

Packs & prices · 1

1 priced

gtin
05909990263516
250 szt.
PLN 159.71

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

81 interactions on record for pyrazinamide.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check pyrazinamide against other medicines How interaction checks work

Pyrazinamide · interactions on record

81 records

4 severe
19 moderate
54 info

Most severe, free to view

LeflunomidL04AA13severe
TeriflunomidL04AA31severe
LeflunomideL04AK01severe
TeriflunomideL04AK02severe

4 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pyrazinamide in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pyrazinamide products

Authorised across Europe · EMA

The same active substance is authorised in 19 EEA countries. Names it is sold under:

Austria · Pyrafat
Belgium · Tebrazid
Bulgaria · Пиразинамид Крка
Germany · Pyrafat, Pyrazinamid Jenapharm
Denmark · Pyrazinamid Sad
Spain · Pirazinamida Prodes
Finland · Tisamid
France · Pirilene
United Kingdom (Northern Ireland) · Pyrazinamide Morningside Healthcare
Greece · Pyrazinamide Genepharm
Croatia · Pyrazinamid Krka
Lithuania · Pyrafat, Pyrazinamide Krka
Luxembourg · Tebrazid
Latvia · Pyrazinamide Olpha
Malta · Pyrazinamide Morningside Healthcare
Netherlands · Pyrazinamide Cf
Portugal · Pramide
Romania · Pirazinamida Atb
Slovenia · Pirazinamid Krka

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/3f8b9052-d246-4209-899b-8d442e84f563
GET /v1/drugs/3f8b9052-d246-4209-899b-8d442e84f563?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "500 mg",
  "packaging": "05909990263516 ¦ Rp ¦ 8521\n250 tabl.",
  "substance": "Pyrazinamidum 500 mg",
  "common_name": "Pyrazinamidum",
  "pl_product_id": "100193964",
  "pozwolenie_nr": "02635",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

API reference MCP server Plans

See everything about pyrazinamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console